Clinical and Translational Results of a Phase II, Randomized Trial of an Anti–IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy

PURPOSE: This phase II trial evaluated the efficacy and safety of cixutumumab, a human anti–insulin-like growth factor receptor 1 (IGF-1R) monoclonal IgG1 antibody, and explored potential biomarkers in postmenopausal women with hormone receptor–positive breast cancer. EXPERIMENTAL DESIGN: Patients w...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Clin Cancer Res
Main Authors: Gradishar, William J., Yardley, Denise A., Layman, Rachel, Sparano, Joseph A., Chuang, Ellen, Northfelt, Donald W., Schwartz, Gary N., Youssoufian, Hagop, Tang, Shande, Novosiadly, Ruslan, Forest, Amelie, Nguyen, Tuan S., Cosaert, Jan, Grebennik, Dmitri, Haluska, Paul
Formato: Artigo
Idioma:Inglês
Publicado: 2015
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5548297/
https://ncbi.nlm.nih.gov/pubmed/26324738
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-0588
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares